JP5087536B2 - 延長された血液半減期を有するトキシンペプチド - Google Patents

延長された血液半減期を有するトキシンペプチド Download PDF

Info

Publication number
JP5087536B2
JP5087536B2 JP2008507949A JP2008507949A JP5087536B2 JP 5087536 B2 JP5087536 B2 JP 5087536B2 JP 2008507949 A JP2008507949 A JP 2008507949A JP 2008507949 A JP2008507949 A JP 2008507949A JP 5087536 B2 JP5087536 B2 JP 5087536B2
Authority
JP
Japan
Prior art keywords
peptide
composition
amino acid
shk
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008507949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538506A5 (enExample
JP2008538506A (ja
Inventor
サリバン，ジヨン・ケイ
マツギバーン，ジヨージフ・ジー
ミランダ，レスリー・ピー
グエン，ヒユン・キユー
ウオーカー，ケネス・ダブリユ
フー，シヨウ−フエン・シルビア
ゲツグ，コリン・ブイ，ジユニア
マクドナフ，ステフアン・アイ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2008538506A publication Critical patent/JP2008538506A/ja
Publication of JP2008538506A5 publication Critical patent/JP2008538506A5/ja
Application granted granted Critical
Publication of JP5087536B2 publication Critical patent/JP5087536B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
JP2008507949A 2005-04-22 2006-04-18 延長された血液半減期を有するトキシンペプチド Expired - Fee Related JP5087536B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67434205P 2005-04-22 2005-04-22
US60/674,342 2005-04-22
US11/406,454 2006-04-17
US11/406,454 US7833979B2 (en) 2005-04-22 2006-04-17 Toxin peptide therapeutic agents
PCT/US2006/015199 WO2006116156A2 (en) 2005-04-22 2006-04-18 Toxin peptides with extended blood halflife

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011276723A Division JP5220915B2 (ja) 2005-04-22 2011-12-19 延長された血液半減期を有するトキシンペプチド

Publications (3)

Publication Number Publication Date
JP2008538506A JP2008538506A (ja) 2008-10-30
JP2008538506A5 JP2008538506A5 (enExample) 2010-02-12
JP5087536B2 true JP5087536B2 (ja) 2012-12-05

Family

ID=37894298

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008507949A Expired - Fee Related JP5087536B2 (ja) 2005-04-22 2006-04-18 延長された血液半減期を有するトキシンペプチド
JP2011276723A Expired - Fee Related JP5220915B2 (ja) 2005-04-22 2011-12-19 延長された血液半減期を有するトキシンペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011276723A Expired - Fee Related JP5220915B2 (ja) 2005-04-22 2011-12-19 延長された血液半減期を有するトキシンペプチド

Country Status (16)

Country Link
US (2) US7833979B2 (enExample)
EP (1) EP1896080A2 (enExample)
JP (2) JP5087536B2 (enExample)
KR (2) KR20100017942A (enExample)
AR (1) AR053234A1 (enExample)
AU (1) AU2006239928B8 (enExample)
BR (1) BRPI0607750A2 (enExample)
CA (1) CA2604999A1 (enExample)
CR (1) CR9452A (enExample)
EA (1) EA013470B1 (enExample)
IL (1) IL186527A0 (enExample)
MX (1) MX2007013031A (enExample)
NO (1) NO20076013L (enExample)
NZ (1) NZ562201A (enExample)
TW (1) TW200716748A (enExample)
WO (1) WO2006116156A2 (enExample)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB0414272D0 (en) * 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
WO2008008873A2 (en) * 2006-07-14 2008-01-17 Georgia Tech Research Corporation Clc channel ligand
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
WO2008088422A2 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
US20080260738A1 (en) * 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
ATE537185T1 (de) 2007-05-14 2011-12-15 Univ Mexico Nacional Autonoma Vm23 und vm24, zwei skorpionpeptide, die humane t-lymphozyten-kaliumkanäle (untertyp kv1.3) mit hoher selektivität blockieren
EP2162540A2 (en) * 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
CA2705289A1 (en) * 2007-11-13 2009-05-22 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
WO2009075773A2 (en) * 2007-12-07 2009-06-18 Goldstein Steven A Identification of toxin ligands
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
KR101200659B1 (ko) 2008-07-23 2012-11-12 한미사이언스 주식회사 세 말단 반응기를 갖는 비펩타이드성 중합체를 이용한 생리활성 폴리펩타이드 약물 결합체
US20110171163A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of ziconotide peptides
MX2011003117A (es) * 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
US20110171161A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of protegrin peptides
US8252228B1 (en) * 2008-10-13 2012-08-28 Abbott Cardiovascular Systems Inc. Methods for sterilizing carriers for treatment of a kidney
CA2755133A1 (en) * 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
US20120134984A1 (en) * 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
TW201129379A (en) 2009-11-20 2011-09-01 Amgen Inc Anti-Orai1 antigen binding proteins and uses thereof
CN106995493B (zh) * 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
WO2011142858A2 (en) * 2010-05-11 2011-11-17 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
US20140072983A1 (en) 2010-08-10 2014-03-13 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
SG10201601789TA (en) 2011-03-16 2016-04-28 Amgen Inc Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
CA2838474A1 (en) 2011-06-06 2012-12-13 Kineta One, Llc Shk-based pharmaceutical compositions and methods of manufacturing and using the same
SG11201401193XA (en) * 2011-10-03 2014-05-29 Univ California TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS
EP2834268B1 (en) * 2011-10-28 2018-07-04 University of Debrecen Modified peptide toxins
WO2013065343A1 (ja) * 2011-10-31 2013-05-10 株式会社 島津製作所 非ペプチドヒンジ部含有フレキシブル抗体様分子
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US9102751B2 (en) 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
KR102498405B1 (ko) 2012-10-11 2023-02-09 다이이찌 산쿄 가부시키가이샤 글리신아미드 화합물의 제조 방법
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
US20140179560A1 (en) 2012-12-10 2014-06-26 Fred Hutchinson Cancer Research Center Drug discovery methods and platforms
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
CN104937105A (zh) 2013-01-25 2015-09-23 詹森生物科技公司 Kv1.3拮抗剂及其使用方法
US9603915B2 (en) * 2013-02-14 2017-03-28 The Board of Trustees of the University of Akansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
US9789209B2 (en) 2013-03-14 2017-10-17 The Regents Of The University Of California, Berke Activatable membrane-interacting peptides and methods of use
CN105814074B (zh) * 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
CA2916725A1 (en) * 2013-07-22 2015-01-29 Kineta One, Llc Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
ES2841173T3 (es) 2013-10-03 2021-07-07 Janssen Biotech Inc Variantes de Protoxina-II y métodos de uso
AU2013404615B2 (en) * 2013-10-28 2018-05-17 Baylor College Of Medicine Novel scorpion toxin analogue and method for treating autoimmune diseases
PT3088419T (pt) * 2013-12-25 2019-01-11 Daiichi Sankyo Co Ltd Conjugado de anticorpo anti-trop2-fármaco
CA2928794C (en) 2014-01-31 2019-08-13 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
WO2015155976A1 (ja) 2014-04-10 2015-10-15 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート
RU2711640C2 (ru) 2014-04-10 2020-01-17 Дайити Санкио Компани, Лимитед Конъюгат анти-her3 антитело-лекарственное средство
GB201408135D0 (en) 2014-05-08 2014-06-25 Conogenetix Biosciences Gmbh Kv1.3 potassium channel antagonists
AU2015274574B2 (en) 2014-06-10 2019-10-10 Amgen Inc. Apelin polypeptides
CN104177489B (zh) * 2014-07-29 2017-03-22 暨南大学 基因重组TNF‑α衍生物RMP16及其制备方法与应用
EP3179857B1 (en) 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
TWI708790B (zh) * 2014-11-07 2020-11-01 美商奇尼塔慢性疼痛有限責任公司 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途
WO2016112208A2 (en) * 2015-01-09 2016-07-14 Kineta One, Llp Topical applications of kv1.3 channel blocking peptides to treat skin inflammation
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
MX2017012654A (es) 2015-04-02 2018-01-09 Janssen Biotech Inc Variantes de protoxina-ii y metodos de uso.
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
CN107922477B (zh) 2015-06-29 2022-11-01 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
BR112018073739A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteína de ligação de albumina sérica de domínio único
CN109641046B (zh) 2016-05-20 2023-11-07 哈普恩治疗公司 单链可变片段cd3结合蛋白质
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
JP6812551B2 (ja) 2016-11-23 2021-01-13 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原結合タンパク質
EP3496742A4 (en) * 2016-12-01 2020-04-08 University Of South Florida PEPTICORPS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING EAR FIBRILLATION
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
KR102537651B1 (ko) 2017-01-17 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US10668113B2 (en) 2017-03-31 2020-06-02 Vivekananda Ramana Formulation for targeting cancer in humans and canines using venom
US10668112B2 (en) 2017-03-31 2020-06-02 Vivekananda Ramana Formulation for targeting cancer in humans and canines
US10668130B2 (en) 2017-03-31 2020-06-02 Vivekananda Ramana Formulation for targeting cancer in humans and canines using chlorotoxin
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
TW202530219A (zh) 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
WO2019012015A1 (en) * 2017-07-12 2019-01-17 Iontas Limited POTASIC CHANNEL INHIBITORS
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
WO2019044946A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
US20200262877A1 (en) * 2017-10-09 2020-08-20 Blaze Bioscience, Inc. Ion channel-binding peptides and methods of use thereof
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
WO2019225296A1 (ja) * 2018-05-24 2019-11-28 国立大学法人熊本大学 薬物送達用担体
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
US12220604B2 (en) 2018-07-31 2025-02-11 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN109106943B (zh) * 2018-11-05 2021-04-20 中国科学院上海有机化学研究所 抗癫痫的毒素Martentoxin及其应用
WO2021053194A1 (en) 2019-09-20 2021-03-25 Zealand Pharma A/S Kv1.3 blockers
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
US20230374084A1 (en) 2020-09-23 2023-11-23 Aldevron, Llc Potent and selective inhibitors of nav1.7
CN112353934B (zh) * 2020-11-23 2023-05-19 中国人民解放军军事科学院军事医学研究院 一种芋螺毒素药物组合物及其冻干制剂
AU2022245193A1 (en) 2021-03-23 2023-09-07 Zealand Pharma A/S Kv1.3 blockers
JP2024511804A (ja) * 2021-03-24 2024-03-15 ジーエルオー ファーマ，インク． 化粧剤の送達のためのマルチソーム脂質小胞
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
CN120265307A (zh) 2022-10-18 2025-07-04 西兰制药公司 抑制剂

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
JPH0669959B2 (ja) 1985-09-26 1994-09-07 東燃株式会社 コレラ毒素類を活性成分とする免疫抑制剤
AU607172B2 (en) 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
DE3875306T2 (de) 1987-02-24 1993-04-01 Xoma Corp Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4925677A (en) 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5397702A (en) 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US4994436A (en) * 1989-03-10 1991-02-19 American Air Liquide Process for safely destroying organic binders in ceramic components during the firing process
US4906159A (en) 1989-03-22 1990-03-06 Caterpillar Industrial Inc. Freely positionable load carrying attachment for an automatic guided vehicle
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
IL98932A0 (en) 1990-07-27 1992-07-15 Univ California Assay,kits and methods based on nk+channel expression
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
JPH0640945A (ja) 1992-07-23 1994-02-15 Kureha Chem Ind Co Ltd Ｆｃフラグメント結合抗腫瘍剤
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5494895A (en) 1993-07-22 1996-02-27 Merck & Co., Inc. Scorpion peptide margatoxin with immunosuppressant activity
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU1843295A (en) 1994-02-23 1995-09-11 Chiron Corporation Method and compositions for increasing the serum half-life of pharmacologically active agents
FR2717688B1 (fr) 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69530325T2 (de) 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5763478A (en) 1996-10-16 1998-06-09 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
US6077680A (en) 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
DE69734451T2 (de) 1996-12-26 2006-07-13 Suntory Limited Skorpion-spezifische neuropeptide
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
SG129211A1 (en) 1997-11-06 2007-02-26 Univ Singapore Therapeutic molecules
US6703485B2 (en) 1997-12-23 2004-03-09 The Trustees Of Columbia University In The City Of New York Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
US6551821B1 (en) 1997-12-23 2003-04-22 The Trustees Of Columbia University In The City Of New York Brain cyclic nucleotide gated ion channel and uses thereof
AU2333999A (en) 1998-01-23 1999-08-09 Prolifaron, Inc. Methods and compositions for the identification of growth factor mimetics, growth factors and inhibitors
JP3530004B2 (ja) 1998-02-06 2004-05-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6166322A (en) * 1999-04-16 2000-12-26 Industrial Technology Research Institute Encapulation process for mono-and polycrystalline silicon solar cell modules
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP2100901A1 (en) 1999-05-17 2009-09-16 ConjuChem Biotechnologies Inc. Modified Insulin and conjugates thereof
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6768002B1 (en) 1999-06-22 2004-07-27 E. I. Du Pont De Nemours And Company Scorpion toxins
AU781793B2 (en) 1999-06-22 2005-06-16 E.I. Du Pont De Nemours And Company Scorpion toxins from buthotus judaicus
US6096891A (en) 1999-12-09 2000-08-01 Air Products And Chemicals, Inc. Process for the production of cyclic N,N'-dialkylureas
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
SE0000935D0 (sv) 2000-03-21 2000-03-21 Astrazeneca Ab An inhalation device
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001259432B2 (en) 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
EP1177806A1 (en) 2000-08-04 2002-02-06 The Technology Partnership Public Limited Company Dry powder inhaler
AU2002233340B2 (en) * 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6861405B2 (en) 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20040152769A1 (en) 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2298785T3 (es) 2003-06-12 2008-05-16 Eli Lilly And Company Proteinas de fusion.
BRPI0406606A (pt) 2003-11-13 2005-12-06 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
EP1796709A4 (en) 2004-10-07 2009-10-28 Univ California ANALOGUES OF TOXIN SHK AND USES IN SELECTIVE INHIBITION OF KV1.3 POTASSIUM CHANNELS
WO2008088422A2 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
CA2755133A1 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3

Also Published As

Publication number Publication date
WO2006116156A3 (en) 2007-10-04
KR20100017942A (ko) 2010-02-16
US20110045587A1 (en) 2011-02-24
CR9452A (es) 2008-05-21
AR053234A1 (es) 2007-04-25
AU2006239928A1 (en) 2006-11-02
CA2604999A1 (en) 2006-11-02
EA013470B1 (ru) 2010-04-30
NZ562201A (en) 2011-03-31
NO20076013L (no) 2008-01-22
US20070071764A1 (en) 2007-03-29
IL186527A0 (en) 2008-01-20
EP1896080A2 (en) 2008-03-12
AU2006239928B2 (en) 2010-12-02
KR20080021606A (ko) 2008-03-07
US8907071B2 (en) 2014-12-09
MX2007013031A (es) 2007-12-12
EA200702313A1 (ru) 2008-06-30
WO2006116156A2 (en) 2006-11-02
TW200716748A (en) 2007-05-01
BRPI0607750A2 (pt) 2009-11-24
AU2006239928B8 (en) 2011-03-31
JP2012100671A (ja) 2012-05-31
JP5220915B2 (ja) 2013-06-26
JP2008538506A (ja) 2008-10-30
US7833979B2 (en) 2010-11-16

Similar Documents

Publication Publication Date Title
JP5087536B2 (ja) 延長された血液半減期を有するトキシンペプチド
US7825093B2 (en) Methods of using OSK1 peptide analogs
CA2687141C (en) Compositions and methods for producing bioactive fusion proteins
ZA200709701B (en) Toxin peptide therapeutic agents
AU2011213759B2 (en) Compositions and methods for producing bioactive fusion proteins
AU2011213760A1 (en) Compositions and methods for producing bioactive fusion proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120904

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120910

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150914

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees